MARKET

BRTX

BRTX

Biorestorative Therapies Inc
NASDAQ
3.010
-0.010
-0.33%
Closed 16:00 01/27 EST
OPEN
3.070
PREV CLOSE
3.020
HIGH
3.070
LOW
2.950
VOLUME
3.84K
TURNOVER
2.14K
52 WEEK HIGH
5.98
52 WEEK LOW
2.460
MARKET CAP
11.06M
P/E (TTM)
-0.2411
1D
5D
1M
3M
1Y
5Y
Roth Capital Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $15
Benzinga · 12/07/2022 13:13
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome -- MELVILLE, N.Y., Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Comp...
GlobeNewswire · 12/06/2022 12:00
EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome
Benzinga · 12/06/2022 11:31
BRIEF-Biorestorative Therapies Enters Into Agreement With Regenexx
Reuters · 12/05/2022 12:04
BioRestorative Therapies Obtains Exclusive Rights to Regenexx's Chronic Lumbar Disc Disease Framework
BioRestorative Therapies Obtains Exclusive Rights to Regenexx's Chronic Lumbar Disc Disease Framework
MT Newswires · 12/05/2022 12:02
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
-- Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones-- MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical sta...
GlobeNewswire · 12/05/2022 12:00
EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease
Benzinga · 12/05/2022 11:30
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022
MELVILLE N.Y., Nov. 29, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City. EventRHK ...
GlobeNewswire · 11/29/2022 16:20
More
About BRTX
BioRestorative Therapies, Inc. is a life sciences company, which is focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. It offers two developmental programs, namely Disc/Spine Program (brtxDisc) and Metabolic Program (ThermoStem), which relate to the treatment of disc/spinedisease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous hypoxic cultured mesenchymal stem cell (MSC) product derived from a patient's own bone marrow and formulated with a biomaterial carrier (platelet lysate). BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. It is engaged in developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (BADSC), to generate brown adipose tissue (BAT).

Webull offers kinds of BioRestorative Therapies Inc stock information, including NASDAQ:BRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BRTX stock methods without spending real money on the virtual paper trading platform.